| Drug class |
Proton‑pump inhibitor (PPI) – blocks the H⁺/K⁺‑ATPase in gastric parietal cells. |
| Common brand names |
Protonix®, PantoSphincter®, etc. (availability varies by country). |
| Indications |
• Gastro‑oesophageal reflux disease (GERD) – erosive and non‑erosive.
• Erosive oesophagitis (grades A–C).
• Zollinger‑Ellison syndrome (accompanied by other therapies).
• Helicobacter pylori eradication regimens (usually as part of a triple or quadruple therapy). |
| Typical adult dosages |
• GERD / reflux oesophagitis – 40 mg PO once daily (or 20 mg if the patient is a low‑dose user).
• Acute erosive oesophagitis – 40 mg PO twice daily for 2–4 weeks, then 40 mg once daily for maintenance.
• H. pylori – 40 mg PO twice daily for 7–14 days (usually combined with a PPI‑based triple or quadruple regimen).
• Zollinger‑Ellison – 40–80 mg PO once or twice daily, titrated to symptom control. |
| Route |
Oral (tablet, delayed‑release capsule, or oral suspension). |
| Contraindications |
• Known hypersensitivity to pantoprazole or any excipient.
• Concomitant use of medications that require acid‑mediated activation (e.g., omeprazole‑activated drugs) if a PPI may interfere. |
| Precautions |
• Pregnancy & lactation – category B (no evidence of risk in humans). Use only if benefits outweigh risks.
• Renal impairment – no dose adjustment needed; however, monitor if severe.
• Hepatic impairment – generally safe; monitor liver function tests in severe cases.
• Long‑term use (>1 yr) – monitor for osteoporosis, hypomagnesemia, and vitamin B₁₂ deficiency. |
| Adverse effects |
• Headache, abdominal pain, diarrhea, constipation, nausea, flatulence, dyspepsia.
• Rare: interstitial lung disease, serious skin reactions (Stevens–Johnson).
• Long‑term: ↓magnesium → paresthesia, seizures; ↓B₁₂ → macrocytic anemia; ↑risk of Clostridioides difficile infection. |
| Drug interactions |
• Clopidogrel – ↓clopidogrel activation; consider alternative antiplatelet.
• Warfarin – ↓INR, increased bleeding risk.
• Ketoconazole – ↓ketoconazole absorption.
• Diazepam, midazolam – ↓CYP3A4 metabolism → ↑serum levels.
• Methotrexate – ↑CYP2C19 inhibition → ↑methotrexate levels. |
| Special populations |
• Elderly – similar dosing, watch for renal function decline.
• Pediatric – dosing by weight (≈1 mg/kg, max 40 mg).
• Patients on dual antiplatelet therapy – weigh benefits vs. bleeding risk. |
| Monitoring |
• Symptom improvement (heartburn, regurgitation).
• If on long‑term therapy, check magnesium, vitamin B₁₂, and bone density as indicated.
• Periodic labs for patients on concomitant drugs that may interact. |
| Storage |
Store at 20–25 °C, protected from moisture and light. Keep out of reach of children. |
| Packaging |
10‑tablet blister packs (40 mg) or 1‑month supply (30‑tablet) common. |